News | February 01, 2023
Sun Pharma Q3 FY23 Gross Sales up 13.1%; Net profit up 5.2%
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
He was appointed a Board member and the Chairman in 2012.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
Subscribe To Our Newsletter & Stay Updated
